U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H28O2
Molecular Weight 288.4244
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIHYDROANDROSTENEDIONE

SMILES

[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)CC[C@]34C

InChI

InChIKey=RAJWOBJTTGJROA-WZNAKSSCSA-N
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-16H,3-11H2,1-2H3/t12-,14-,15-,16-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H28O2
Molecular Weight 288.4244
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22064602 | https://www.ncbi.nlm.nih.gov/pubmed/3783591 | https://www.ncbi.nlm.nih.gov/pubmed/28733189 | https://www.ncbi.nlm.nih.gov/pubmed/27449532 | https://www.ncbi.nlm.nih.gov/pubmed/10359391

Dihydroandrostenedione (Androstanedione) is a steroid metabolite and a precursor of both testosterone and estrone normally produced by the adrenal gland and gonads and is converted to testosterone through the action of 17β-hydroxysteroid dehydrogenase, which is found in most body tissues. Androstenedione is also produced by some plants and has recently been marketed as a product for increasing blood testosterone concentrations to be used as a natural alternative to anabolic steroid use. However, androstenedione administration during resistance training did not significantly alter the serum testosterone concentration in normotestosterogenic young men. The increased muscle size and strength observed with resistance training were also not augmented with androstenedione administration. The use of androstenedione increased the serum concentrations of estradiol and estrone, suggesting an increased aromatization of the ingested androstenedione and/or testosterone derived from the exogenous androstenedione. The use of androstenedione was associated with decreased levels of HDL-C. These data provide evidence that androstenedione does not enhance adaptations to resistance training and may result in potentially serious adverse health consequences in young men.

Originator

Sources: Z. physiol. Chem. (1934), 229, 185-91.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
20.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Synthesis of testosterone and 5alpha-androstanediols during nutritionally stimulated gonadal growth in Lytechinus variegatus lamarck (Echinodermata:Echinoidea).
1998 Aug
Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase.
2003 Nov
Metabolism of estrogens and androgens by scleractinian corals.
2003 Nov
Inhibition of 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD) activity of human lung microsomes by genistein, daidzein, coumestrol and C(18)-, C(19)- and C(21)-hydroxysteroids and ketosteroids.
2005 Jul
Persistence and pathways of testosterone dissipation in agricultural soil.
2005 May-Jun
Androgen metabolism via 17beta-hydroxysteroid dehydrogenase type 3 in mammalian and non-mammalian vertebrates: comparison of the human and the zebrafish enzyme.
2005 Oct
Mechanism of proton transfer in the 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni.
2007 Nov 23
Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
2008 Mar
Two homologous fungal carbonyl reductases with different substrate specificities.
2009 Mar 16
Patents

Patents

Sample Use Guides

During weeks 1, 2, 4, 5, 7, and 8, the men were randomized to either androstenedione, 300 mg/d (n = 10), or placebo (n = 10).
Route of Administration: Oral
Ishikawacells were treated with increasing concentrations of A4 (Androstanedione) (0-1000 pmol) for 4 days. Cell proliferation was measured by the (4,5-dimethylthiaxol-2-yi)-2,5-diphenyltetraxolium bromide (MTT) assay. Apoptosis was analyzed through Annexin-V/propidium iodide (PI) staining and flow cytometry: 17β-hydroxy steroid dehydrogenase type 1 (17β-HSD1) and aromatase mRNA expression was measured by reverse transcription-polymerase chain reaction (RT-PCR). Western blotting was used to detect cell signaling expressions of Akt/MAPK. A4 treatment (1 nM) decreased cell proliferation and increased apoptosis, as demonstrated by MTT and flow cytometry or related gene expression. The cellular responses induced by A4 treatment were mediated by activation of the Akt and MAPK signaling pathway. Treatment had no effect on 17β-HSD1 and aromatase expression.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:21:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:21:47 GMT 2023
Record UNII
2KR72RNR8Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIHYDROANDROSTENEDIONE
Common Name English
DIHYDRO-ANDROSTENEDIONE
Common Name English
ANDROSTANE-3,17-DIONE
Systematic Name English
5.ALPHA.-ANDROSTANEDIONE
Systematic Name English
5.ALPHA.-ANDROSTANE-3,17-DIONE
Systematic Name English
NSC-9897
Code English
ANDROSTANE-3,17-DIONE, (5.ALPHA.)-
Systematic Name English
ANDROSTANEDIONE
Systematic Name English
NSC-60796
Code English
5.ALPHA.-ANDROSTA-3,17-DIONE
Common Name English
Classification Tree Code System Code
DEA NO. 4000
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
NCI_THESAURUS C2289
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
CFR 21 CFR 862.1430
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
Code System Code Type Description
CAS
846-46-8
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
NSC
9897
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
CHEBI
15994
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
NSC
60796
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID80233576
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
DRUG BANK
DB01561
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
WIKIPEDIA
Androstanedione
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
NCI_THESAURUS
C107155
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY NCIT
ECHA (EC/EINECS)
212-685-5
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
CHEBI
22542
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
PUBCHEM
222865
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
FDA UNII
2KR72RNR8Z
Created by admin on Fri Dec 15 15:21:47 GMT 2023 , Edited by admin on Fri Dec 15 15:21:47 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE
IN VITRO
Related Record Type Details
ACTIVE MOIETY